Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to -$13.5 million.

  • Outlook Therapeutics' Income towards Parent Company changed N/A to -$13.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$93.3 million, marking a year-over-year decrease of 43316.81%. This contributed to the annual value of -$62.4 million for FY2025, which is 1717.18% up from last year.
  • Per Outlook Therapeutics' latest filing, its Income towards Parent Company stood at -$13.5 million for Q4 2025.
  • In the past 5 years, Outlook Therapeutics' Income towards Parent Company ranged from a high of -$13.3 million in Q3 2025 and a low of -$46.4 million during Q1 2025